Participants 541 655 7
five cohorts comprising 40 individuals with a single administration of A4250 (0.1, 0.3, 1, 3, or 10 mg) or placeb
Participants 660 793 3
 three cohorts comprising 24 individuals with a 1-week administration of A4250 (1 or 3 mg once daily or 1.5 mg twice daily) or plac
Participants 1774 1814 3
 benefit to patients with cholestatic li
